首页> 外文期刊>Arthritis research & therapy. >Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus
【24h】

Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus

机译:拮抗剂介导的Toll样受体下调增加了人乳头瘤病毒感染在系统性红斑狼疮中的流行

获取原文
获取原文并翻译 | 示例
       

摘要

Introduction: Prevalence of an abnormal Papanicolaou smear was significantly increased in lupus patients in cross-sectional studies, associated with a higher prevalence of high-risk human papillomavirus (HPV) infection. The nucleic acid-specific Toll-like receptors (TLRs) locate at the endolysosomal compartments and trigger the induction of cytokines for the innate immune response. This study evaluated whether abnormal host innate immune response in lupus patients may enhance HPV persistence.Methods: Protein levels of TLRs 3, 7, 8 and 9 in cervical epithelial cells of lupus patients and controls with or without HPV infection were assessed using flow cytometry. Characteristics associated with the differential expression of TLRs in systemic lupus erythematosus (SLE) were elucidated. The effect and interferon-stimulated genes (ISGs) (ISG15 and Mx-1) gene expressions were then measured in oncogenic HeLa (HPV18), CaSki (HPV) and C33A (HPV negative) cell lines using flow cytometry and quantitative real-time PCR. Ex vivo productions of cytokines and interferon-gamma (IFN-γ) upon TLR ligands stimulations were subsequently measured using cytometric bead array and ELISA.Results: For subjects with HPV infection, levels of TLR3 and TLR7 were significantly lower in lupus patients compared with controls. Significantly decreased TLRs 7, 8 and 9 levels were observed in HPV-negative SLE compared to healthy controls. For SLE with and without HPV infection, TLR7 and 9 levels were significantly lower in infected SLE than those in HPV-negative patients. Independent explanatory variables associated with down-regulation of TLR7 level included HPV infection and a higher cumulative dose of prednisolone; while a higher cumulative dose of hydroxychloroquine and HPV infection were associated with down-regulation of TLR9 level. In cervical cell lines, TLRs 3, 7, 8, 9 protein levels and antiviral ISG15 and Mx-1 gene expressions were inhibited in two oncogenic HPV types. Functional data showed that the induction of pro-inflammatory cytokines by TLR ligands (R837, ssRNA and ODN2395) was greatly impaired in CaSki and HeLa than C33A cells.Conclusions: In conclusion, prednisolone and TLR antagonist (hydroxychloroquine) may down-regulate protein levels of TLR7 and TLR9 in lupus patients, thereby decreasing the innate immune response against HPV infection. Upon infection, HPV further down-regulate TLR7 and 9 levels for viral persistence. Furthermore, reduction of nucleic acid-sensing TLRs 7, 8 and 9 in carcinogenic HPVs ensures that the expression of inducible pro-inflammatory cytokines is minimized to prevent the expression of antiviral ISGs (ISG15 and Mx-1) on a biologically relevant antiviral response.
机译:简介:在横断面研究中,狼疮患者的异常Papanicolaou涂片的患病率显着增加,与高危人类乳头瘤病毒(HPV)感染的患病率较高相关。核酸特异的Toll样受体(TLR)位于溶酶体区室,并触发对先天免疫应答的细胞因子的诱导。这项研究评估了狼疮患者的异常宿主先天免疫反应是否可以增强HPV持久性。方法:使用流式细胞术评估狼疮患者宫颈上皮细胞以及有或没有HPV感染的对照组中TLRs 3、7、8和9的蛋白水平。阐明了与系统性红斑狼疮(SLE)中TLR差异表达相关的特征。然后使用流式细胞仪和定量实时PCR在致癌的HeLa(HPV18),CaSki(HPV)和C33A(HPV阴性)细胞系中测量效应和干扰素刺激基因(ISG15和Mx-1)基因表达。随后使用细胞计数珠阵列和ELISA测定了TLR配体刺激后的细胞因子和干扰素-γ(IFN-γ)的体外产生。结果:对于HPV感染的受试者,狼疮患者的TLR3和TLR7的水平明显低于对照组。 。与健康对照相比,HPV阴性的SLE中观察到TLR 7、8和9的水平明显降低。对于有或没有HPV感染的SLE,感染的SLE中的TLR7和9水平显着低于HPV阴性患者。与TLR7水平下调相关的独立解释变量包括HPV感染和泼尼松龙的累积剂量较高;而较高的羟氯喹累积剂量和HPV感染与TLR9水平下调有关。在两种致癌HPV类型中,宫颈细胞系中的TLR 3、7、8、9蛋白水平以及抗病毒ISG15和Mx-1基因表达受到抑制。功能数据表明,与C33A细胞相比,CaSki和HeLa细胞中TLR配体(R837,ssRNA和ODN2395)对促炎细胞因子的诱导作用大大减弱。结论:泼尼松龙和TLR拮抗剂(羟氯喹)可能下调蛋白质水平。狼疮患者中TLR7和TLR9的表达,从而降低了针对HPV感染的先天免疫应答。感染后,HPV会进一步下调TLR7和9水平以保持病毒持久性。此外,减少致癌性HPV中的核酸敏感TLR 7、8和9可确保将诱导型促炎细胞因子的表达降至最低,从而防止抗病毒ISG(ISG15和Mx-1)在生物学上相关的抗病毒应答中表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号